Search

Your search keyword '"Doyle L"' showing total 2,114 results

Search Constraints

Start Over You searched for: Author "Doyle L" Remove constraint Author: "Doyle L"
2,114 results on '"Doyle L"'

Search Results

1. A possible misaligned orbit for the young planet AU Mic c

2. Impact Of Ketogenic Diet On Athletes: Current Insights

3. Atmospheric characterisation and tighter constraints on the orbital misalignment of WASP-94 A b with HARPS

4. WASP-131 b with ESPRESSO I: A bloated sub-Saturn on a polar orbit around a differentially rotating solar-type star

5. Measuring spatio-temporal couplings using modal spatio-spectral wavefront retrieval

6. The hot Neptune WASP-166 b with ESPRESSO III: A blue-shifted tentative water signal constrains the presence of clouds

7. The Hot Neptune WASP-166~b with ESPRESSO I: Refining the Planetary Architecture and Stellar Variability

8. The Hot Neptune WASP-166 b with ESPRESSO II: Confirmation of atmospheric sodium

9. TESS observations of southern ultra fast rotating low mass stars

10. Probing the Origin of Stellar Flares on M dwarfs Using TESS Data Sectors 1-3

11. Investigating the Rotational Phase of Stellar Flares on M dwarfs Using K2 Short Cadence Data

12. THEME 12 CLINICAL MANAGEMENT AND SUPPORT.

15. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial

16. Preparation and characterization of Mn(II)Mn(III) complexes with relevance to class Ib ribonucleotide reductases

17. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

18. Kepler-62: A five-planet system with planets of 1.4 and 1.6 Earth radii in the Habitable Zone

19. Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

20. Extrasolar planet detection by binary stellar eclipse timing: evidence for a third body around CM Draconis

21. A Prototype for the PASS Permanent All Sky Survey

22. Timing Detection of Eclipsing Binary Planets and Transiting Extrasolar Moons

24. A search for Jovian-mass planets around CM Draconis using eclipse minima timing

26. Near-Term Detectability of Terrestrial Extrasolar Planets: TEP Network Observations of CM Draconis

32. WASP-131 b with ESPRESSO – I. A bloated sub-Saturn on a polar orbit around a differentially rotating solar-type star

34. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

35. Supplementary Table 1 from Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

36. Supplemental Figure 1 from A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report

39. Supplementary Figure Legends from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

40. Supplemental Table 1 from A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report

41. Supplementary Figure 4 from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

42. Supplementary Figure 1 from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

46. Supplementary Figure 1 from Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

47. Supplementary Materials from Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms

48. Supplementary Figure 3 from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

49. Supplementary Figure 2B from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

Catalog

Books, media, physical & digital resources